# Lithium Therapeutic Drug Monitoring; Once Daily Vs Twice Daily Dosing and the Impact of Kidney Function

> **NCT03811860** · NA · UNKNOWN · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 15 (estimated)

## Conditions studied

- Bipolar Disorder
- Major Depressive Disorder

## Interventions

- **DIAGNOSTIC_TEST:** Lithium level
- **DIAGNOSTIC_TEST:** Serum Creatinine

## Key facts

- **NCT ID:** NCT03811860
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-06
- **Primary completion:** 2019-09
- **Final completion:** 2019-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811860, "Lithium Therapeutic Drug Monitoring; Once Daily Vs Twice Daily Dosing and the Impact of Kidney Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03811860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*